Introduction
============

Radiation treatment, which is an essential therapeutic tool for pelvic malignancies, can cause both acute and chronic radiation proctitis. Acute radiation proctitis (ARP) is defined as occurring within 3 months of radiotherapy and is often self-limiting. Chronic radiation proctitis (CRP) occurs 3 to 6 months after radiotherapy or even years later ([@b1-etm-0-0-6464]--[@b4-etm-0-0-6464]). The clinical symptoms of CRP include diarrhea, rectal pain, increased defecate frequency, tenesmus, rectal bleeding, strictures, deep ulcers and fistulas. Although the symptoms of many CRP patients may spontaneously, for some patients who are more critically ill, it may develop to persistent rectal bleeding, deep ulcers and even fistulas that may deeply affect the patient\'s quality of life ([@b5-etm-0-0-6464],[@b6-etm-0-0-6464]). Nowadays, there are no clearly defined treatment guidelines for CRP and therapeutic modalities include topical and oral agents, endoscopic treatments, formalin application, hyperbaric oxygen therapy (HBOT) and surgery. To date, the majority of clinical trials have focused on controlling rectal bleeding, which is thought to be a common complication of CRP ([@b7-etm-0-0-6464]--[@b9-etm-0-0-6464]). Although a deep rectal ulcer is not as common as rectal bleeding in CRP patients, persistent deep rectal ulcers may result in complications, such as stricture and fistulas. However, the data available on the treatment of CRP with deep ulcers is limited and requires further study.

Mesalazine, also known as 5-aminosalicylic acid (5-ASA), has been extensively studied in inflammatory bowel disease and the majority of the data has shown that it is a simple, safe and effective way to treat ulcerative colitis and Crohn\'s disease. Numerous studies have been performed to investigate the efficacy of 5-ASA and its precursors in the treatment of CRP but the results were inconsistent ([@b10-etm-0-0-6464]--[@b13-etm-0-0-6464]). Mesalazine is formulated for oral ingestion and rectal administration. A previous study conducted by Seo *et al* ([@b12-etm-0-0-6464]) demonstrated that a combination of oral and topical mesalazine may be a safe and effective treatment of the first episode of CRP, particularly for hemorrhagic proctitis. Unlike previous studies, the present study pays more attention to CRP with rectal ulcers. The aim of the present study was to evaluate the efficacy and safety of topical mesalazine suppository in the treatment of CRP with rectal ulcers.

Patients and methods
====================

### Subjects

Between January 2010 and December 2015, 10 patients that were diagnosed with refractory CRP were recruited at The Second Affiliated Hospital of Guangxi Medical University (Nanning, China). Exclusion criteria were: i) Patients with other bowel disease and with a history of prior irradiation to the pelvis or prior rectal ulcers; ii) patients with relapse or metastasis of a primary tumor and iii) patients who received surgery as part of the treatment of cancer. All patients that were enrolled had deep rectal ulcers and had not responded to previous conventional therapy, including sucralfate, corticosteroids, antibiotic, probiotics and traditional Chinese medicine. All patients were evaluated by the severity of the proctitis by clinical symptoms and endoscopic examination prior to the treatment. Furthermore, patient demographics and clinical data, including age, radiotherapy dose and previous treatment options, were collected. Written informed consent was obtained from all participants. The study was approved by the Ethics Committee of The Second Affiliated Hospital of Guangxi Medical University (Nanning, China).

### Treatment methods

All patients were administered 0.5 g topical mesalazine suppository (Salofalk; Dr. Falk Pharma GmbH, Freiburg, Germany) twice daily for 6 months. During the 2 weeks prior to mesalazine suppository, all patients did not receive any treatments in order to exclude the confounding factors. Patients were followed up by telephone or by an outpatient department visit at 2, 4, 8, 12 and 24 weeks after the initiation of treatment to collect clinical data. Endoscopic evaluation was performed before and after treatment.

### Condition assessment criteria

All patients were evaluated by a combination of clinical symptoms and endoscopic examination. Clinical symptoms were graded based on the Subjective Objective Management Analysis (SOMA) scale ([Table I](#tI-etm-0-0-6464){ref-type="table"}). There is no standard endoscopic evaluation criterion for ulcerative CRP. Therefore, the following five common endoscopic characteristics associated with radiation proctitis were evaluated blindly by two endoscopists, mean scores were reported as the final scores: Telangiectasia, edema, ulceration, stenosis and necrosis ([Table II](#tII-etm-0-0-6464){ref-type="table"}).

### Statistical analysis

All data were analyzed using SPSS statistical package version 22.0 (IBM SPSS, Armonk, NY, USA). Continuous variables were presented as the means with standard deviation or median (range) according to data distributions. A paired, two-tailed Student\'s t-test was performed to compare clinical symptoms scores and endoscopic examination scores. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

### Patients and treatments

A total of 10 female patients, which underwent radiotherapy due to cervical cancer and were diagnosed with refractory CRP, were enrolled in the present study. Demographics and clinical data of the patients, including radiation dose and previous treatment options, are listed in [Table III](#tIII-etm-0-0-6464){ref-type="table"}. The mean age of all patients was 48.80 years (range, 35-60 years). The mean interval from the conclusion of radiotherapy to the onset of symptoms was 7.6 months (range, 2-12 months), and the mean duration of symptoms before treatment was 7.9 months (range, 5-15 months). The median hemoglobin level was 101.3 g/dl (range, 37.9-126.6 g/dl), and only 2 patients required a blood transfusion before the treatment was initiated.

### Symptom score

The SOMA scale was assessed before and 2, 4, 8, 12, 24 weeks after the initiation of treatment. Following treatment, there were statistically significant improvements in all symptoms. The mean pre-treatment total symptom score was 8.20 and the post-treatment mean score was 0.90. A total of 50% (5/10) of the patients acquired a clinically complete response (post-treatment total symptom score of 0). Additionally, there were reductions in the mean scores for rectal bleeding (2.40 vs.0.30; P\<0.01), rectal pain (2.00 vs. 0.50; P\<0.01), stool frequency (2.00 vs. 0.10; P\<0.01) and tenesmus (1.80 vs. 0.00; P\<0.01) before and 24 weeks after the initiation of treatment. The pre- and post-treatment median symptoms scores are shown in [Table IV](#tIV-etm-0-0-6464){ref-type="table"}.

A comparison of the total scores at baseline and at week 2 revealed that the difference was statistically significant (P\<0.01), demonstrating that the majority of the patients responded within 2 weeks of treatment initiation. Furthermore, when comparing other symptom scores during the treatment period, the data showed that the median time to improvement of rectal bleeding, stool frequency, tenesmus and rectal pain with mesalazine suppository treatment was 2, 4 and 8 weeks ([Table IV](#tIV-etm-0-0-6464){ref-type="table"}). Furthermore, no patient experienced worsening of his or her symptoms.

### Endoscopic score

A total of 9 patients received endoscopic examinations before and at 24 weeks after initiation of treatment. Only 1 patient who suffered vagina-rectum fistula rejected endoscopic examinations after treatment. After treatment, the mean pre-treatment total symptom score was 9.22 and with a post-treatment mean of 5.22 (P\<0.01). In total, 2 patients (20%) experienced complete ulcer healing. Additionally, there were reductions in the mean scores for telangiectasia (pre vs. post-treatment, 2.78 vs. 1.89; P=0.009), mucosal edema (2.89 vs. 1.78; P=0.001) and mucosal ulcers (2.44 vs. 0.89; P=0.003). However, statistical reductions in the median symptom scores were not observed for stenosis (0.78 vs. 0.67; P=0.347) and necrosis (0.33 vs. 0.00; P=0.081; [Table V](#tV-etm-0-0-6464){ref-type="table"}). The patient who suffered vagina-rectum fistula still had a fistula after treatment. The main pathological changes before and after treatment under endoscopic examination are shown in [Fig. 1](#f1-etm-0-0-6464){ref-type="fig"}.

Discussion
==========

The present study assessed the efficacy and safety of the mesalazine suppository in the treatment for CRP patients complicated with rectal ulcers. The data demonstrated that the majority of the patients experienced relief of rectal bleeding, tenesmus, stool frequency and rectal pain symptoms. Furthermore, endoscopic observations showed that this therapy promotes rectal ulceration healing in CRP patients.

Radiation proctitis, which is one of the most common intestinal complications following radiation therapy for pelvic malignancies, can be divided into acute and chronic radiation proctitis. Although radiotherapy techniques have been developed and novel devices exist that spare the rectal exposure, CRP still occurs in 5-20% of patients after radiotherapy. For mild CRP, they can be resolved spontaneously without any treatment, whereas severe symptoms of CRP, including persistent rectal bleeding, deep ulceration, strictures and fistulas, have a worse prognosis and require treatment to control symptoms ([@b4-etm-0-0-6464],[@b14-etm-0-0-6464]). Furthermore, several treatment options, including drug therapy, endoscopic treatments, formalin application, HBOT and surgery have been used to relieve symptoms of CRP, but none of them have shown convincing efficacy ([@b2-etm-0-0-6464],[@b15-etm-0-0-6464]).

Previous studies have focused on hemorrhagic CRP ([@b7-etm-0-0-6464]--[@b9-etm-0-0-6464]), whereas the present study concentrated on CRP patients with rectal ulcerations. All of the patients enrolled in the present study had rectal ulcerations and were not responsive to previous treatment modalities. Furthermore, rectal ulceration is not a common complication for CRP, but persistent deep rectal ulceration accompanies evident symptoms and is more likely to lead to stricture, perforation and fistula. Until recently, experiments for treatments of deep ulceration CRP were limited. Although several drugs, including topical sucralfate ([@b9-etm-0-0-6464]), intestinal probiotics ([@b16-etm-0-0-6464],[@b17-etm-0-0-6464]), steroid enemas ([@b18-etm-0-0-6464]), short chain fatty acids ([@b19-etm-0-0-6464],[@b20-etm-0-0-6464]), antioxidants ([@b21-etm-0-0-6464]), antibiotics ([@b22-etm-0-0-6464]), pentoxifylline ([@b23-etm-0-0-6464]) synbiotics ([@b17-etm-0-0-6464]) and traditional Chinese medicine ([@b24-etm-0-0-6464]) have been used to relieve symptoms of CRP, studies revealed that superior results were observed in patients with mild-to-moderate CRP.

Novel endoscopic therapies, including argon plasma coagulation (APC) and radiofrequency ablation (RFA), are preferred alternatives to control persistent rectal bleeding of CRP ([@b25-etm-0-0-6464]--[@b27-etm-0-0-6464]). However, these invasive treatments are not suitable for patients with deep ulceration. The ulceration lesions involve the intestinal muscle and even the serosa layers. Furthermore, invasive endoscopic treatment should be avoided for ulcerative CRP because these treatments may pose the risk of perforation and fistula ([@b28-etm-0-0-6464]--[@b31-etm-0-0-6464]). Additionally, intrarectal formalin application also exhibited effective control of rectal bleeding in patients with CRP ([@b26-etm-0-0-6464],[@b27-etm-0-0-6464]). However, the side effects of formalin application include anal stenosis, fissures, fecal incontinence and ulceration of the mucosa; therefore, it was not a good choice for ulcerative CRP ([@b32-etm-0-0-6464],[@b33-etm-0-0-6464]). Furthermore, although HBOT is reported to be an effective treatment for CRP, it is not widely applicable due to its high cost and the specialized equipment required ([@b34-etm-0-0-6464],[@b35-etm-0-0-6464]). Finally, surgery is thought to be the last resort for CRP because of its severe postoperative complications. Therefore, surgery may only be applied for severe and refractory CRP patients who are not responsive to other medical and endoscopic approaches ([@b36-etm-0-0-6464],[@b37-etm-0-0-6464]).

Mesalazine, the active component of sulfasalazine, is considered as an anti-inflammatory drug used to treat inflammatory bowel disease, including ulcerative colitis and Crohn\'s disease. Furthermore, mesalazine suppository is a bowel-specific formulation that acts locally in the rectum and can increase drug mucosal concentrations and decrease systemic side effects. A number of clinical trials have been performed to investigate the efficacy of 5-ASA and its precursors in the prevention and treatment of radiation proctitis; however, the conclusions remain controversial, with some studies reporting positive results and others showing no effect or even worsening of the symptoms ([@b10-etm-0-0-6464]--[@b13-etm-0-0-6464]). Based on previous results, the present study attempted to evaluate the efficacy and safety of topical mesalazine suppository in the treatment of refractory ulcerative CRP. After 24 weeks of therapy, the clinical symptoms were relieved and an endoscopic examination showed marked improvements in the rectal mucosa damage. These results were consistent with the results of Seo *et al* ([@b12-etm-0-0-6464]), who conducted a prospective study to investigate the combination therapy with oral and topical mesalazine for patients with a first episode of radiation. After 4 weeks of treatment, they observed that there were statistically significant improvements in rectal bleeding; however, this treatment cannot control the symptoms of pain, tenesmus and stool frequency. Endoscopic observations, including telangiectasia, bleeding point and friable mucosa, also showed a statistically significant improvement after 4 weeks of combination treatment. The present study found that mesalazine suppository therapy was able to not only control rectal bleeding but also relieve the symptoms of tenesmus, stool frequency and rectal pain in CRP. These contradictory observations may be due to a difference in the treatment time between the two studies. Patients in the present study received mesalazine suppository for 24 weeks whereas in the study by Seo *et al* ([@b12-etm-0-0-6464]) the patients received only 4 weeks of combination treatment. Furthermore, the present study revealed that rectal bleeding and stool frequency could be alleviated after 2 weeks of treatment, while longer treatments of at least 4 weeks were required to improve the symptoms of tenesmus. Additionally, rectal pain requires at least 8 weeks of treatment for it to be relieved. In the present study, a statistically significant improvement was observed not only in telangiectasia but also in the mucosal edema and ulcerations after longer mesalazine suppository treatment.

The present study had various limitations. There were a small number of cases and no control group. Furthermore, the period of follow-up was not long enough to evaluate the long-term efficacies and complications. In conclusion, compared to other special therapies that are performed in selected centers by skilled operators, have potential complications and are expensive, mesalazine suppository may be a feasible and effective treatment for CRP, particularly in patients with ulcers.
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###### 

Subjective Objective Management Analysis assessment criteria for chronic radiation proctitis symptoms.

  Score   Bleeding         Pain           Stool frequency   Tenesmus
  ------- ---------------- -------------- ----------------- ------------
  1       Not obvious      Occasional     2-4 times/day     Occasional
  2       \>2 times/week   Intermittent   4-8 times/day     Frequent
  3       Often            Sustained      \>8 times/day     Sustained
  4       Gross            Refractory     Out of control    Refractory

###### 

Scoring of endoscopic characteristics for chronic radiation proctitis.

  Score   Telangiectasia           Congestion/edema        Ulceration                    Stenosis                               Necrosis
  ------- ------------------------ ----------------------- ----------------------------- -------------------------------------- ----------
  1       Focal telangiectasia     Focal reddening         Superficial ulcer \<1 cm^2^   Lumen diameter, \>2/3 normal range     Yes
  2       Multiple non-confluent   Diffuse non-confluent   Superficial ulcer \>1 cm2     Lumen diameter, 1/3-2/3 normal range   No
  3       Multiple confluent       Diffuse confluent       Deep ulceration               Lumen diameter, \<1/3 normal range     No
  4       --                       --                      Perforation/fistula           Obstruction                            No

###### 

Characteristics of all patients.

  Case   Age (years)   Neoplasm staging   Hypertension   Diabetes   Smoking history   Interval^[a](#tfn1-etm-0-0-6464){ref-type="table-fn"}^ (months)   Duration^[b](#tfn2-etm-0-0-6464){ref-type="table-fn"}^ (months)   HGB (g/l)   Previous treatment^[c](#tfn3-etm-0-0-6464){ref-type="table-fn"}^
  ------ ------------- ------------------ -------------- ---------- ----------------- ----------------------------------------------------------------- ----------------------------------------------------------------- ----------- ------------------------------------------------------------------
    1    42            IIIA               No             No         No                4                                                                 4.0                                                               85.0        2-6
    2    35            IIIB               No             No         No                8                                                                 17.0                                                              37.9        1-6
    3    58            IIIB               No             No         No                7                                                                 2.5                                                               126.6       1,5
    4    46            IIA                No             No         No                9                                                                 3.0                                                               124.3       4-6
    5    41            IIIB               No             No         No                7                                                                 3.0                                                               104.5       1,2,6
    6    49            IIB                No             No         No                8                                                                 2.0                                                               100.0       4-6
    7    52            IIIB               No             No         No                2                                                                 3.0                                                               104.2       5,6
    8    46            IIB                No             No         No                9                                                                 8.0                                                               51.4        3,4,6
    9    59            IIB                Yes            No         No                12                                                                3.0                                                               100.3       4,6
  10     60            IIB                No             No         No                10                                                                6.0                                                               102.3       4,6

Time from the end of radiotherapy to the onset of chronic radiation proctitis symptoms.

Time from the onset of symptoms to mesalazine suppository treatment.

Previous treatment included 1, sucralfate enema; 2, glucocorticoid enema; 3, montmorillonite powder; 4, L-glutamine; 5, antibiotic treatment; and 6, Yunnan baiyao Traditional Chinese Medicine enema. HGB, hemoglobin.

###### 

Symptom scores of patients pre- and post-treatment.

  Time (weeks)   Total score   P-value   Rectal bleeding   P-value   Pain        P-value   Stool frequency   P-value   Tenesmus    P-value
  -------------- ------------- --------- ----------------- --------- ----------- --------- ----------------- --------- ----------- ---------
  Baseline       8.20±3.39     --        2.40±0.97         --        2.00±0.94   --        2.00±1.05         --        1.80±1.03   --
  2              5.50±3.37     \<0.01    1.30±0.95         0.003     1.70±1.16   0.081     1.00±0.94         \<0.01    1.50±0.97   0.081
  4              3.60±2.91     \<0.01    0.80±0.79         \<0.01    1.50±1.27   0.052     0.40±0.70         \<0.01    0.90±0.74   0.004
  8              1.60±1.90     \<0.01    0.40±0.52         \<0.01    0.90±0.99   \<0.01    0.10±0.32         \<0.01    0.20±0.42   \<0.001
  12             1.30±1.89     \<0.01    0.30±0.48         \<0.01    0.80±1.03   \<0.01    0.10±0.32         \<0.01    0.10±0.32   \<0.001
  24             0.90±1.29     \<0.01    0.30±0.48         \<0.01    0.50±0.71   \<0.01    0.10±0.32         \<0.01    --          \<0.001

Data are presented as the mean ± standard deviation.

###### 

Endoscopic scores of patients pre- and post-treatment.

  Time point   Total score   Telangiectasia   Edema       Ulceration   Stenosis    Necrosis
  ------------ ------------- ---------------- ----------- ------------ ----------- -----------
  Baseline     9.22±1.99     2.78±0.44        2.89±0.33   2.44±1.24    0.78±0.44   0.33±0.50
  24 weeks     5.22±1.39     1.89±0.60        1.78±0.67   0.89±1.27    0.67±0.50   --
  P-value      \<0.01        0.009            0.001       0.003        0.347       0.081

Data are presented as the mean ± standard deviation.
